Risk factor
Very poor trading liquidity
Profitability factor
Weak growth
About
Bioptik Technology Incorporation operates as a global entity, focusing on the creation and distribution of medical instruments and diagnostic chemicals. The company's product line encompasses the EasyMate series of blood glucose monitoring systems, as well as comprehensive diagnostic devices designed to measure blood glucose, cholesterol, and uric acid levels, complete with their essential test strips. Beyond its healthcare offerings, Bioptik also provides a range of skincare solutions, including those formulated with hyaluronic acid, alongside various dietary supplements. Uniquely, the company diversifies its business by supplying biodiesel products. Founded in 1999, Bioptik Technology Incorporation is headquartered in Zhunan, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on EV/EBIT